Literature DB >> 26176401

Linezolid for XDR-TB--Final Study Outcomes.

Myungsun Lee1, Sang Nae Cho, Clifton E Barry, Taeksun Song, Youngran Kim, Ina Jeong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26176401      PMCID： PMC6402791          DOI： 10.1056/NEJMc1500286

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.

Authors:  Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

2.  Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.

Authors:  Shenjie Tang; Lan Yao; Xiaohui Hao; Xia Zhang; Gang Liu; Xin Liu; Meiying Wu; Linhai Zen; Hua Sun; Yidian Liu; Jin Gu; Feishen Lin; Xiafang Wang; Zhanjun Zhang
Journal:  Eur Respir J       Date:  2014-09-18       Impact factor: 16.671

Review 3.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Authors:  Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Jan-William C Alffenaar; Holly A Anger; Jose A Caminero; Paolo Castiglia; Saverio De Lorenzo; Giovanni Ferrara; Won-Jung Koh; Giesela F Schecter; Tae S Shim; Rupak Singla; Alena Skrahina; Antonio Spanevello; Zarir F Udwadia; Miquel Villar; Elisabetta Zampogna; Jean-Pierre Zellweger; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-04-10       Impact factor: 16.671

4.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

5.  Timing of relapse in short-course chemotherapy trials for tuberculosis.

Authors:  A J Nunn; P P J Phillips; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2010-02       Impact factor: 2.373
  5 in total
  19 in total

1.  Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Authors:  Andreas H Diacon; Elana van Brakel; Nacer Lounis; Paul Meyvisch; Ben Van Baelen; Tine De Marez; Eilidh Jenkins; Brian Dannemann
Journal:  Am J Respir Crit Care Med       Date:  2017-12-15       Impact factor: 21.405

2.  Caught between two proteins: a mycobacterial inhibitor challenges the mold.

Authors:  Helena I Boshoff
Journal:  Mol Microbiol       Date:  2016-12-12       Impact factor: 3.501

3.  Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.

Authors:  Rui Pi; Xiaomin Chen; Jian Meng; Qingyun Liu; Yiwang Chen; Cheng Bei; Chuan Wang; Qian Gao
Journal:  Antimicrob Agents Chemother       Date:  2022-10-03       Impact factor: 5.938

4.  Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.

Authors:  Kristina M Bigelow; Rokeya Tasneen; Yong S Chang; Kelly E Dooley; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.

Authors:  Saqib Kidwai; Chan-Yong Park; Shradha Mawatwal; Prabhakar Tiwari; Myung Geun Jung; Tannu Priya Gosain; Pradeep Kumar; David Alland; Sandeep Kumar; Avinash Bajaj; Yun-Kyung Hwang; Chang Sik Song; Rohan Dhiman; Ill Young Lee; Ramandeep Singh
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.

Authors:  G L Drusano; Jenny Myrick; Michael Maynard; Jocelyn Nole; Brandon Duncanson; David Brown; Stephan Schmidt; Michael Neely; C A Scanga; Charles Peloquin; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Nanoparticle-mediated macrophage targeting-a new inhalation therapy tackling tuberculosis.

Authors:  Shaimaa Makled; Nabila Boraie; Noha Nafee
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

8.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

9.  Moving Beyond Directly Observed Therapy for Tuberculosis.

Authors:  John Z Metcalfe; Max R O'Donnell; David R Bangsberg
Journal:  PLoS Med       Date:  2015-09-15       Impact factor: 11.069

10.  Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.

Authors:  Taeksun Song; Myungsun Lee; Han-Seung Jeon; Yumi Park; Lori E Dodd; Véronique Dartois; Dean Follman; Jing Wang; Ying Cai; Lisa C Goldfeder; Kenneth N Olivier; Yingda Xie; Laura E Via; Sang Nae Cho; Clifton E Barry; Ray Y Chen
Journal:  EBioMedicine       Date:  2015-10-09       Impact factor: 8.143
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.